Natural Antibodies to Tumor-Associated Antigens

  • Sheila María Álvarez-Fernández
  • Lucia De Monte
  • Massimo AlessioEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1393)


Natural autoantibodies raised by humoral immune response to cancer can be exploited to identify potential tumor-associated antigens (TAAs), and might constitute new putative prognostic and/or diagnostic biomarkers. Here we describe how sera from tumor patients can be used to identify TAAs by screening antibody immunoreactivity against the cancer proteome resolved by two-dimensional gel electrophoresis.

Key words

2D-electrophoresis Immunoproteomics Tumor-associated antigens Autoantibodies Western blot 



M.A. is supported by AIRC. Special Program Molecular Clinical Oncology 5 per mille n.9965, and IG-10538.


  1. 1.
    Tureci O, Sahin U, Pfreundschuh M (1997) Serological analysis of human tumor antigens: molecular definition and implications. Mol Med Today 3:342–349CrossRefPubMedGoogle Scholar
  2. 2.
    Imafuku Y, Omenn GS, Hanash S (2004) Proteomics approaches to identify tumor antigen directed autoantibodies as cancer biomarkers. Dis Markers 20:149–153CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Caron M, Choquet-Kastylevsky G, Joubert-Caron R (2007) Cancer immunomics using autoantibody signatures for biomarker discovery. Mol Cell Proteomics 6:1115–1122CrossRefPubMedGoogle Scholar
  4. 4.
    Mou Z, He Y, Wu Y (2009) Immunoproteomics to identify tumor-associated antigens eliciting humoral response. Cancer Lett 278:123–129CrossRefPubMedGoogle Scholar
  5. 5.
    Zhu Q, Liu M, Dai L et al (2013) Using immunoproteomics to identify tumor-associated antigens (TAAs) as biomarkers in cancer immunodiagnosis. Autoimmun Rev 12:1123–1128, doi: S1568-9972(13)00119-5CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Le Naour F (2001) Contribution of proteomics to tumor immunology. Proteomics 1:1295–1302CrossRefPubMedGoogle Scholar
  7. 7.
    Klade CS, Voss T, Krystek E et al (2001) Identification of tumor antigens in renal cell carcinoma by serological proteome analysis. Proteomics 1:890–898CrossRefPubMedGoogle Scholar
  8. 8.
    De Monte L, Sanvito F, Olivieri S et al (2008) Serological immunoreactivity against colon cancer proteome varies upon disease progression. J Proteome Res 7:504–514CrossRefPubMedGoogle Scholar
  9. 9.
    Tomaino B, Cappello P, Capello M et al (2011) Circulating autoantibodies to phosphorylated alpha-enolase are a hallmark of pancreatic cancer. J Proteome Res 10:105–112CrossRefPubMedGoogle Scholar
  10. 10.
    Zhou W, Capello M, Fredolini C et al (2010) Mass spectrometry analysis of the post-translational modifications of alpha-enolase from pancreatic ductal adenocarcinoma cells. J Proteome Res 9:2929–2936CrossRefPubMedGoogle Scholar
  11. 11.
    Murphy MA, O’Leary JJ, Cahill DJ (2012) Assessment of the humoral immune response to cancer. J Proteomics 75:4573–4579CrossRefPubMedGoogle Scholar
  12. 12.
    Lichtenfels R, Kellner R, Atkins D et al (2003) Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses. Biochim Biophys Acta 1646:21–31CrossRefPubMedGoogle Scholar
  13. 13.
    Seliger B, Menig M, Lichtenfels R et al (2003) Identification of markers for the selection of patients undergoing renal cell carcinoma-specific immunotherapy. Proteomics 3:979–990CrossRefPubMedGoogle Scholar
  14. 14.
    Unwin RD, Harnden P, Pappin D et al (2003) Serological and proteomic evaluation of antibody responses in the identification of tumor antigens in renal cell carcinoma. Proteomics 3:45–55CrossRefPubMedGoogle Scholar
  15. 15.
    Prasannan L, Misek DE, Hinderer R et al (2000) Identification of beta-tubulin isoforms as tumor antigens in neuroblastoma. Clin Cancer Res 6:3949–3956PubMedGoogle Scholar
  16. 16.
    Cui JW, Li WH, Wang J et al (2005) Proteomics-based identification of human acute leukemia antigens that induce humoral immune response. Mol Cell Proteomics 4:1718–1724CrossRefPubMedGoogle Scholar
  17. 17.
    Forgber M, Gellrich S, Sharav T et al (2009) Proteome-based analysis of serologically defined tumor-associated antigens in cutaneous lymphoma. PLoS One. doi: 10.1371/journal.pone.0008376 Google Scholar
  18. 18.
    Forgber M, Trefzer U, Sterry W et al (2009) Proteome serological determination of tumor-associated antigens in melanoma. PLoS One. doi: 10.1371/journal.pone.0005199 Google Scholar
  19. 19.
    Le Naour F, Brichory F, Misek DE et al (2002) A distinct repertoire of autoantibodies in hepatocellular carcinoma identified by proteomic analysis. Mol Cell Proteomics 1:197–203CrossRefPubMedGoogle Scholar
  20. 20.
    Brichory F, Beer D, Le Naour F et al (2001) Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res 61:7908–7912PubMedGoogle Scholar
  21. 21.
    Cui L, Zhiqiang X, Zhuchu C et al (2006) Proteome analysis of human lung squamous carcinoma. Proteomics 6:547–558CrossRefGoogle Scholar
  22. 22.
    He P, Naka T, Serada S et al (2007) Proteomics-based identification of alpha-enolase as a tumor antigen in non-small lung cancer. Cancer Sci 98:1234–1240CrossRefPubMedGoogle Scholar
  23. 23.
    Le Naour F, Misek DE, Krause MC et al (2001) Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin Cancer Res 7:3328–3335PubMedGoogle Scholar
  24. 24.
    Hamrita B, Chahed K, Kabbage M et al (2008) Identification of tumor antigens that elicit a humoral immune response in breast cancer patients’ sera by serological proteome analysis (SERPA). Clin Chim Acta 393:95–102CrossRefPubMedGoogle Scholar
  25. 25.
    Hong SH, Misek DE, Wang H et al (2004) An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer. Cancer Res 64:5504–5510CrossRefPubMedGoogle Scholar
  26. 26.
    Tomaino B, Cappello P, Capello M et al (2007) Autoantibody signature in human ductal pancreatic adenocarcinoma. J Proteome Res 6:4025–4031CrossRefPubMedGoogle Scholar
  27. 27.
    Tsunemi S, Nakanishi T, Fujita Y et al (2010) Proteomics-based identification of a tumor-associated antigen and its corresponding autoantibody in gastric cancer. Oncol Rep 23:949–956PubMedGoogle Scholar
  28. 28.
    He Y, Wu Y, Mou Z et al (2007) Proteomics-based identification of HSP60 as a tumor-associated antigen in colorectal cancer. Proteomics Clin Appl 1:336–342CrossRefPubMedGoogle Scholar
  29. 29.
    He Y, Mou Z, Li W et al (2009) Identification of IMPDH2 as a tumor-associated antigen in colorectal cancer using immunoproteomics analysis. Int J Colorectal Dis 24:1271–1279CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Sheila María Álvarez-Fernández
    • 1
  • Lucia De Monte
    • 2
  • Massimo Alessio
    • 1
    Email author
  1. 1.Proteome Biochemistry UnitIRCCS San Raffaele HospitalMilanoItaly
  2. 2.Tumor Immunology UnitIRCCS San Raffaele HospitalMilanoItaly

Personalised recommendations